Sign In
Buy SRTS
Sensus Healthcare Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | -$0.125 |
| EPS actual | -$0.160 |
| EPS Surprise | -28.00% |
| Revenue estimate | 5.323M |
| Revenue actual | 3.394M |
| Revenue Surprise | -36.24% |
| Release date | Feb 12, 2026 |
| EPS estimate | -$0.0550 |
| EPS actual | -$0.190 |
| EPS Surprise | -245.45% |
| Revenue estimate | 8.345M |
| Revenue actual | 4.939M |
| Revenue Surprise | -40.81% |
| Release date | Nov 06, 2025 |
| EPS estimate | -$0.110 |
| EPS actual | -$0.0600 |
| EPS Surprise | 45.45% |
| Revenue estimate | 6.313M |
| Revenue actual | 6.884M |
| Revenue Surprise | 9.05% |
| Release date | Aug 07, 2025 |
| EPS estimate | $0.0100 |
| EPS actual | -$0.0600 |
| EPS Surprise | -700.00% |
| Revenue estimate | 6.313M |
| Revenue actual | 7.315M |
| Revenue Surprise | 15.88% |
Last 4 Quarters for Sensus Healthcare
Below you can see how SRTS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $5.35 |
| EPS estimate | $0.0100 |
| EPS actual | -$0.0600 |
| EPS surprise | -700.00% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $5.58 |
| Aug 04, 2025 | $5.50 |
| Aug 05, 2025 | $5.25 |
| Aug 06, 2025 | $5.33 |
| Aug 07, 2025 | $5.35 |
| Aug 08, 2025 | $3.47 |
| Aug 11, 2025 | $3.18 |
| Aug 12, 2025 | $3.27 |
| Aug 13, 2025 | $3.42 |
| 4 days before | -4.12% |
| 4 days after | -36.07% |
| On release day | -35.23% |
| Change in period | -38.71% |
| Release date | Nov 06, 2025 |
| Price on release | $3.52 |
| EPS estimate | -$0.110 |
| EPS actual | -$0.0600 |
| EPS surprise | 45.45% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $3.19 |
| Nov 03, 2025 | $3.10 |
| Nov 04, 2025 | $3.48 |
| Nov 05, 2025 | $3.69 |
| Nov 06, 2025 | $3.52 |
| Nov 07, 2025 | $4.20 |
| Nov 10, 2025 | $4.34 |
| Nov 11, 2025 | $4.21 |
| Nov 12, 2025 | $4.60 |
| 4 days before | 10.34% |
| 4 days after | 30.68% |
| On release day | 19.32% |
| Change in period | 44.20% |
| Release date | Feb 12, 2026 |
| Price on release | $4.65 |
| EPS estimate | -$0.0550 |
| EPS actual | -$0.190 |
| EPS surprise | -245.45% |
| Date | Price |
|---|---|
| Feb 06, 2026 | $5.04 |
| Feb 09, 2026 | $4.91 |
| Feb 10, 2026 | $4.91 |
| Feb 11, 2026 | $4.76 |
| Feb 12, 2026 | $4.65 |
| Feb 13, 2026 | $3.86 |
| Feb 17, 2026 | $3.83 |
| Feb 18, 2026 | $3.85 |
| Feb 19, 2026 | $3.91 |
| 4 days before | -7.74% |
| 4 days after | -15.91% |
| On release day | -16.99% |
| Change in period | -22.42% |
| Release date | May 07, 2026 |
| Price on release | $4.11 |
| EPS estimate | -$0.125 |
| EPS actual | -$0.160 |
| EPS surprise | -28.00% |
| Date | Price |
|---|---|
| May 01, 2026 | $3.98 |
| May 04, 2026 | $3.96 |
| May 05, 2026 | $3.93 |
| May 06, 2026 | $4.09 |
| May 07, 2026 | $4.11 |
| May 08, 2026 | $3.08 |
| May 11, 2026 | $3.41 |
| May 12, 2026 | $3.37 |
| May 13, 2026 | $3.45 |
| 4 days before | 3.27% |
| 4 days after | -16.06% |
| On release day | -25.06% |
| Change in period | -13.32% |
Sensus Healthcare Earnings Call Transcript Summary of Q1 2026
Sensus Healthcare views 2026 as a transition year driven by the implementation of new, dedicated CPT codes for superficial radiotherapy (SRT). Management laid out five priorities: market education/training, driving adoption under the new reimbursement environment, growing recurring/utilization-based revenue (including Fair Deal Agreements and new software SensusLink), diversifying commercial channels (including financing and international expansion), and delivering sustainable profitability. Q1 shipments totaled 14 systems (10 direct, 4 under Fair Deal/rental), treatment volumes were up 8% year-over-year, and the installed base is ~965 systems globally. Q1 revenue was $3.4M (down from $8.3M YoY) primarily due to zero sales to the company’s historically largest customer; excluding that customer from the prior-year period, revenue rose versus $2.7M. Gross margin declined to 29.2% (from 52.2%) due to product mix (more international shipments and Fair Deal placements). Adjusted EBITDA was negative $4.2M and net loss was $2.6M ($0.16/share). The company ended Q1 with $18.3M cash, no debt, and $16.5M inventory. Management expects Q2 revenue to be higher than Q1, the second half of 2026 to be stronger than the first half, continued pipeline momentum from dermatology conferences (AAD), and progression toward full-year profitability as recurring revenues (FDA, service, SensusLink) and a diversified customer base scale.
